Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
- Eli Lilly: Q2 2026 acquired IPR&D charges estimated at $2.80B pre-tax.